Editors and Contributors

Editors

Contributors

Chapter 1 - Risk Factors

Comber H. National Cancer Registry, Cork, Ireland

Chapter 2 - Screening

Sankatsing V.D.V. Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Netherlands

de Koning H.J. Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Netherlands

Chapter 3 - Prognosis

Vissers P.A.J. Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands. 

van Erning F.N. Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands

Lemmens V.E.P.P. Department of Research, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands

Chapter 4 - Cancer Registries 

Visser O. Department of Registration, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands

Chapter 5 - Drug Development (Including Phase I Trials) 

D’Incalci M. Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy

Fuso Nerini I. Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy

Fotia V. Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy

Chapter 6 - Randomised Trials

Clarke M. Northern Ireland Clinical Trials Unit and Northern Ireland Methodology Hub, Queen’s University Belfast, Belfast, UK

Chapter 7 - Choice of Outcomes (Including Core Outcome Sets and Surrogate Outcomes)

Bellei M. Dipartimento di Medicina Diagnostica, Clinica e di Sanità Pubblica, Università di Modena e Reggio Emilia, Modena, Italy

Guida A. Dipartimento di Oncologia ed Ematologia, Azienda Ospedaliero-universitaria Policlinico di Modena, Modena, Italy

Chapter 8 - Statistical Issues (Including Subgroups, Time-To-Event Analyses, Multiplicity)

Hoster E. Department of Internal Medicine III, University Hospital Munich; IBE - Institute for Medical Information Processing, Biometry and Epidemiology, Ludwig-Maximilians-University Munich, Munich, Germany.

Chapter 9 - Systematic Reviews: A Key to Support Evidence-Informed Decision Making

Florez I.D. Health Research Methodology Program, McMaster University, Hamilton, Canada; Department of Pediatrics, Universidad de Antioquia, Medellin, Colombia

Levine O. Department of Oncology, McMaster University, Hamilton, Canada

Brouwers M.C. Department of Oncology and Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton; Escarpment Cancer Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, Canada

Chapter 10 - Clinical Research in Rare Cancers

Desar I.M.E. Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, Netherlands

Constantinidou A. Medical School University of Cyprus and BoC Oncology Centre, Nicosia, Cyprus

van der Graaf W.T.A. Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, Netherlands; The Institute of Cancer Research & The Royal Marsden Hospital, Sutton, UK

Chapter 11 - How to Become a Researcher

Templeton A.J. Department of Medical Oncology, St. Claraspital Basel and Faculty of Medicine, University of Basel, Basel, Switzerland

Ocana A. Department of Medical Oncology and Translational Research Unit, Albacete University Hospital, Albacete, Spain

Tannock I.F. Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Department of Medicine, University of Toronto, Toronto, Canada

Declarations of Interest

Chapter 1

  • Dr Comber has reported no conflict of interest

Chapter 2

  • Dr Sankatsing has reported no conflict of interest
  • Dr de Koning has reported no conflict of interest

Chapter 3

  • Dr Vissers has reported no conflict of interest
  • Dr van Erning has reported no conflict of interest
  • Prof Dr Lemmens has reported no conflict of interest

Chapter 4

  • Dr Visser has reported no conflict of interest

Chapter 5

  • Dr D’Incalci has reported no conflict of interest
  • Dr Fuso Nerini has reported no conflict of interest
  • Dr Fotia has reported no conflict of interest

Chapter 6

  • Professor Clarke has reported no conflict of interest

Chapter 7

  • Dr Bellei has reported no conflict of interest
  • Dr Guida has reported no conflict of interest

Chapter 8

  • Dr Hoster has reported no conflict of interest

Chapter 9

  • Dr Florez has reported no conflict of interest
  • Dr Levine has reported no conflict of interest
  • Dr Brouwers has reported no conflict of interest

Chapter 10

  • Dr Desar has reported no conflict of interest
  • Dr Constantinidou has reported no conflict of interest
  • Professor van der Graaf has received research grants from GlaxoSmithKline and Novartis

Chapter 11

  • Dr Templeton has performed consultancy for Astellas, Janssen, Sanofi, and Bristol-Myers Squibb (all without personal compensation)
  • Dr Ocana has received research funding from Entrechem
  • Dr Tannock is Chair of IDMC committees for trials sponsored by Janssen and Roche

Reviewers

We would like to thank Dr Emiliano Calvo and all the authors for their time spent reviewing the chapters.

« Previous Page Next Page »

Last update: 11 June 2018